Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oral antiresorptive therapy.

Ira Pande1, David J Hosking

  • 1Department of Medicine, City Hospital, Hucknall Road, Nottingham NG5 1PB, United Kingdom. dhosking@ncht.trent.nhs.uk

Current Osteoporosis Reports
|July 23, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Secukinumab-induced hepatitis and renal vasculitis.

Rheumatology (Oxford, England)·2026
Same author

The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2023
Same author

Sjogren's myelitis presenting as hemicord syndrome.

Clinical medicine (London, England)·2023
Same author

Trials and tribulations in managing a complex case of psoriatic arthritis-a success story in the real world.

Rheumatology advances in practice·2022
Same author

Zoledronate.

Bone·2020
Same author

Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?

Rheumatology (Oxford, England)·2017

Newer oral antiresorptive agents offer improved osteoporosis management through flexible dosing and administration. Their potential extends to managing bone loss in chronic inflammatory diseases, though direct fracture endpoint comparisons are lacking.

Area of Science:

  • Pharmacology
  • Bone Metabolism
  • Osteoporosis Management

Background:

  • Oral antiresorptive agents are crucial for managing osteoporosis.
  • Newer agents like ibandronate present evolving treatment options.
  • Bone loss is a concern in conditions like organ transplantation and cystic fibrosis.

Purpose of the Study:

  • To discuss the effects and future role of newer oral antiresorptive agents.
  • To explore alternative dosing and administration for improved osteoporosis treatment.
  • To examine the application of antiresorptive agents in other chronic diseases and combination therapies.

Main Methods:

  • Review of current literature on oral antiresorptive agents.
  • Discussion of ibandronate and its administration.

Related Experiment Videos

  • Analysis of studies on osteoporosis management in organ transplantation and cystic fibrosis.
  • Evaluation of combination therapy with alendronate and teriparatide.

    • Main Results:

    • Alternative dosing and administration of antiresorptive agents may enhance compliance and tolerability.
    • These agents show promise in mitigating bone loss in non-osteoporosis-specific conditions.
    • Combining antiresorptive agents with anabolic agents like teriparatide yielded disappointing results.

    Conclusions:

    • Oral antiresorptive agents, including newer options like ibandronate, are vital for osteoporosis.
    • Expanded use in chronic inflammatory diseases is a potential future direction.
    • A significant limitation is the absence of direct comparative fracture data between agents.